Novo Nordisk A/S logo

NOVO B - Novo Nordisk A/S Share Price

DKK440.9 6.5  1.5%

Last Trade - 3:16pm

Large Cap
Market Cap £117.11bn
Enterprise Value £116.83bn
Revenue £14.80bn
Position in Universe 2nd / 1830
Unlock NOVO B Revenue
Relative Strength (%)
1m -4.33%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -7.16%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
107,927 111,780 111,696 111,831 122,021 126,946 132,264 144,655 +3.3%
+24.3 +18.7 +2.3 +2.9 +5.3 +8.3 +5.66 +12.2
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, NovoNordisk A/S revenues increased 4% to DKR126.95B. Net incomeincreased 8% to DKR42.14B. Revenues reflect Diabetes andobesity segment increase of 5% to DKR108.02B, Europesegment increase of 47% to DKR34.3B, Region China segmentincrease of 10% to DKR14.08B, USA segment increase of 1% toDKR57.82B. Net income benefited from Diabetes and obesitysegment income increase of 3% to DKR43.74B.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for NOVO B
Graphical History


NOVO B Revenue Unlock NOVO B Revenue

Net Income

NOVO B Net Income Unlock NOVO B Revenue

Normalised EPS

NOVO B Normalised EPS Unlock NOVO B Revenue

PE Ratio Range

NOVO B PE Ratio Range Unlock NOVO B Revenue

Dividend Yield Range

NOVO B Dividend Yield Range Unlock NOVO B Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NOVO B EPS Forecasts Unlock NOVO B Revenue
Profile Summary

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated November 28, 1931
Public Since May 17, 1974
No. of Shareholders: n/a
No. of Employees: 44,723
Sector Healthcare
Industry Pharmaceuticals
Index FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSEurofirst 300 Ex UK, FTSE Global 100,
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 2,312,500,000
Free Float (0.0%)
Eligible for
NOVO B Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for NOVO B
Upcoming Events for NOVO B
Wednesday 5th May, 2021
Q1 2021 Novo Nordisk A/S Earnings Release
Wednesday 5th May, 2021
Q1 2021 Novo Nordisk A/S Earnings Call
Wednesday 12th May, 2021
Novo Nordisk A/S at Bank of America Global Research Healthcare Conference (Virtual)
Tuesday 18th May, 2021
Novo Nordisk A/S at Berenberg US Conference (Virtual)
Thursday 5th August, 2021
Q2 2021 Novo Nordisk A/S Earnings Release
Thursday 5th August, 2021
Q2 2021 Novo Nordisk A/S Earnings Call
Frequently Asked Questions for Novo Nordisk A/S
What is the Novo Nordisk A/S share price?

As of 3:16pm, shares in Novo Nordisk A/S are trading at DKK440.9, giving the company a market capitalisation of £117.11bn. This share price information is delayed by 15 minutes.

How has the Novo Nordisk A/S share price performed this year?

Shares in Novo Nordisk A/S are currently trading at DKK440.9 and the price has moved by 6.88% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Novo Nordisk A/S price has moved by -16.84% over the past year.

What are the analyst and broker recommendations for Novo Nordisk A/S?

Of the analysts with advisory recommendations for Novo Nordisk A/S, there are there are currently 4 "buy" , 10 "hold" and 2 "sell" recommendations. The overall consensus recommendation for Novo Nordisk A/S is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Novo Nordisk A/S next release its financial results?

Novo Nordisk A/S is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Novo Nordisk A/S dividend yield?

The Novo Nordisk A/S dividend yield is 2.09% based on the trailing twelve month period.

Does Novo Nordisk A/S pay a dividend?

Last year, Novo Nordisk A/S paid a total dividend of 9.1, and it currently has a trailing dividend yield of 2.09%. Looking ahead, Novo Nordisk A/S has not announced an ex-dividend date yet.

When does Novo Nordisk A/S next pay dividends?

Novo Nordisk A/S has yet to annouce their ex-dividend date. The historic dividend yield on Novo Nordisk A/S shares is currently 2.09%.

How do I buy Novo Nordisk A/S shares?

To buy shares in Novo Nordisk A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Novo Nordisk A/S?

Shares in Novo Nordisk A/S are currently trading at DKK440.9, giving the company a market capitalisation of £117.11bn.

Where are Novo Nordisk A/S shares listed? Where are Novo Nordisk A/S shares listed?

Here are the trading details for Novo Nordisk A/S:

Country of listing: Denmark
Exchange: CPH
Ticker Symbol: NOVO B
What kind of share is Novo Nordisk A/S?

Based on an overall assessment of its quality, value and momentum, Novo Nordisk A/S is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Novo Nordisk A/S share price forecast 2021?

Shares in Novo Nordisk A/S are currently priced at DKK440.9. At that level they are trading at 6.79% discount to the analyst consensus target price of 0.00.

Analysts covering Novo Nordisk A/S currently have a consensus Earnings Per Share (EPS) forecast of 19.197 for the next financial year.

How can I tell whether the Novo Nordisk A/S share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novo Nordisk A/S. Over the past six months, the relative strength of its shares against the market has been -20.8%. At the current price of DKK440.9, shares in Novo Nordisk A/S are trading at 0.49% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Novo Nordisk A/S PE Ratio?

The Novo Nordisk A/S PE ratio based on its reported earnings over the past 12 months is 23.91. The shares are currently trading at DKK440.9.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Novo Nordisk A/S?

Novo Nordisk A/S's management team is headed by:

Stig Stroebaek - DRC
Mads Krogsgaard Thomsen - EVP
Anne Kverneland - DRC
Lars Fruergaard Joergensen - PRE
Jeppe Christiansen - VCH
Helge Lund - CHM
Maziar Doustdar - COO
Doug Langa - EVP
Kasim Kutay - DRC
Camilla Sylvest - EVP
Mette Boejer Jensen - DRC
Thomas Rantzau - DRC
Karsten Munk Knudsen - CFO
Ludovic Helfgott - EVP
Monique Carter - EVP
Who are the major shareholders of Novo Nordisk A/S?

Here are the top five shareholders of Novo Nordisk A/S based on the size of their shareholding:

Novo A/S Holding Company
Percentage owned: 6.72% (121.7m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2.38% (43.1m shares)
Statens Pensjonsfond Utland Mutual Fund
Percentage owned: 2.38% (43.1m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.25% (40.8m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 1.47% (26.6m shares)
Similar to NOVO B
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.